{"schema_version":"1.0","type":"article","title":"投資人請注意，下一個減肥藥級別賽道來了！","url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.md","lang":"zh-Hant","date":"2026-08-06","publish_at":"2026-08-06T08:00:00+08:00","updated_at":"2026-08-06","category":"商業分析系列","topic":"商業分析系列","tags":["安宏生醫","AH-001","雄性禿","掉髮新藥","AR 降解劑","PROTAC","禮來","Veradermics","Absci","台灣生技"],"summary":"禮來用 4,000 萬美元卡位掉髮新藥；當美國約 8,000 萬名患者仍受限於兩款老藥，安宏 AH-001 的二期數據可能成為下一次全球資產重估關鍵。","key_points":[],"facts":[],"sections":["01｜為什麼說掉髮新藥有「減肥藥級別」的商業爆發結構？","02｜真正被低估的，不是患者數，而是「沒有被釋放的需求」","03｜華爾街已經先投票：一顆掉髮藥，撐起近 50 億美元估值","04｜禮來已經下場：從 Olumiant、Veradermics 到 ABS-201","05｜下一輪引爆點，會從三種「新治療類別」同時出現","06｜安宏 AH-001 的特殊地位：站在「新機制、局部用藥、可規模化」交叉點","07｜為什麼 AH-001 有機會取得巨大價值？關鍵不是「AI」，而是產品輪廓","08｜安宏的第二層機會：一款掉髮藥，可能驗證整個成藥平台","09｜投資人應該看什麼？三個節點決定下一次價值重估","結語｜禮來已經買票，安宏等待下一張真正能引爆市場的成績單","參考資料"],"references":[{"title":"本文依公開公司公告、監管文件、臨床試驗登錄與市場資料整理；公司自述與市場估算均以原發布者口徑呈現。","source":"","date":"","url":""},{"title":"[Veradermics","source":"S-1：美國型態性落髮患者、治療滲透率、滿意度與市場估算]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026001651/veradermicsincs-1.htm"},{"title":"[Veradermics","source":"Study 302 Phase 2/3 正向頂線資料（2026-04-27）]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/exhibit991-8xk.htm"},{"title":"[Investor's Business Daily","source":"Study 302 公布後股價單日反應]","date":"","url":"https://www.investors.com/news/technology/veradermics-ipo-stock-oral-rogaine/"},{"title":"[Eli Lilly","source":"Olumiant（baricitinib）嚴重圓禿適應症]","date":"","url":"https://olumiant.lilly.com/alopecia-areata"},{"title":"[Veradermics","source":"IPO Prospectus：禮來認購意向（非具約束力）]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026005505/veradermicsinc424b4.htm"},{"title":"[Absci","source":"Prospectus Supplement：4,000 萬美元股份配置給 Eli Lilly]","date":"","url":"https://investors.absci.com/static-files/5d70b681-4b5b-4830-9578-3a0e8473b3f4"},{"title":"[Absci","source":"ABS-201 for Androgenetic Alopecia／HEADLINE Phase 1/2a]","date":"","url":"https://www.absci.com/abs-201-case-study/"},{"title":"[ClinicalTrials.gov","source":"AH-001 Phase I，NCT06927960]","date":"","url":"https://clinicaltrials.gov/study/NCT06927960"},{"title":"[AnHorn Medicines","source":"AH-001 完成美國 Phase I（2025-10-30）]","date":"","url":"https://www.anhornmed.com/zh-hant/news/ai-design-ah001-protein-degrader-phase1-complete/"},{"title":"[AnHorn Medicines","source":"AH-008 取得 FDA IND clearance 與 CDE Index Case designation]","date":"","url":"https://www.anhornmed.com/news/ah008-ind-cipn/"},{"title":"[Kintor Pharmaceutical","source":"KX-826 Phase III 達主要終點]","date":"","url":"https://en.kintor.com.cn/news_details/22.html"},{"title":"[Kintor Pharmaceutical","source":"GT20029 中國 Phase II 達主要終點]","date":"","url":"https://en.kintor.com.cn/news_details/1803365125008502784.html"}],"images":[{"alt":"Veradermics Study 302 的毛髮計數與患者自評結果圖","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-01.png"},{"alt":"全球掉髮新藥競爭地圖與主要治療機制","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-02.png"},{"alt":"從刺激毛囊到局部降解雄激素受體的治療機制演進","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-03.png"},{"alt":"安宏 AIMCADD 與蛋白質降解平台的臨床資產飛輪","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-06）。投資人請注意，下一個減肥藥級別賽道來了！。https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}